Brace yourself. Valeant Pharmaceuticals International (VRX) is on the move. Getty Images The drug maker’s stock price has spiked dramatically, after it reported third quarter per-share profit that blew past expectations thanks to organic growth in its Bausch & Lomb eye-care business and reaffirmed its full-year adjusted EBITDA forecast despite divestitures. Not everyone is excited. Mizuho […]